Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00055224 · ClinicalTrials.gov registry record · NA

Expectation of Unpleasant Events in Anxiety Disorders

A NA study, sponsored by National Institute of Mental Health (NIMH).

Completed
Registry status
NA
Development phase
921
Enrollment target

NCT00055224: Completed NA study, sponsored by National Institute of Mental Health (NIMH).

NCT00055224 is a NA study that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 921 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (34% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00055224, a NA study, has completed, sponsored by National Institute of Mental Health (NIMH).

COMPLETED
Registry status
NA
Development phase
921 participants
Enrollment target

Study Summary

Fear and anxiety are normal responses to a threat. However, anxiety is considered abnormal when the response to the threat is excessive or inappropriate. This study will examine changes in the body and brain that occur during unpleasant learning experiences in healthy volunteers with high, moderate, and low levels of anxiety. A high degree of generalized anxiety is a component of many anxiety disorders and is regarded as a marker of vulnerability for these disorders. People with anxiety disorders and individuals with high degrees of anxiety have inappropriate expectations of unpleasant events. This study will investigate the development of expecting unpleasant events in healthy volunteers with varying degrees of anxiety using aversive conditioning models. A later phase of the study will enroll participants with anxiety disorders and compare their responses to those of healthy volunteers. Patients who meet criteria for an anxiety disorder, and healthy volunteers who have no history of psychiatric or major medical illness will be enrolled in this study. Volunteers will come to the NIH Clinical Center three times for outpatient testing....

Primary Outcome

Subjects participated in go/no go (GNG) task condition during periods of threat of shocks and periods of safety when no shock could be administered. During the GNG stimuli were presented on a monitor. In the GNG task, participants were asked to respond to frequent 'go' stimuli ('=') by pressing the '2' on the keypad of a computer keyboard and to withhold their response to infrequent 'nogo' stimuli ('O'). Stimuli were randomly distributed. A correct go hit was a response recorded during these 200

Interventions

  • DEVICE Threat of shock

Trial Details

FieldValue
Enrollment Target 921 participants
Start Date 2003-03-24
Est. Completion 2022-07-28
Phase NA

What the finished NCT00055224 record still lists

NCT00055224 is an interventional study that assigns participants to a tested intervention. The registered 921 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (34% lower).

The record links to 0 conditions, and to 1 intervention - of which Threat of shock is the first listed.

NCT00055224 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00055224 about?

NCT00055224 is a clinical study titled "Expectation of Unpleasant Events in Anxiety Disorders". Fear and anxiety are normal responses to a threat. However, anxiety is considered abnormal when the response to the threat is excessive or inappropriate. This study will examine changes in the body and brain that occur during unpleasant learning experiences in healthy volunteers with high, moderate,...

What is the current status of trial NCT00055224?

This trial is currently completed. It is a NA study. The enrollment target is 921 participants. The study started on 2003-03-24. Estimated completion is 2022-07-28.

What interventions are being tested in trial NCT00055224?

The interventions under investigation include: Threat of shock (DEVICE).

Who is sponsoring clinical trial NCT00055224?

This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00055224's enrollment target sits among peer trials

921 123rd of 2000 higher than 1,878 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07151001 · 922 participants

    Pivotal Trial of Automated Artificial Intelligence (AI) Based System for Early Diagnosis of Diabetic Retinopathy

  • NCT04589845 · 920 participants · Phase 2

    Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

  • NCT06109870 · 920 participants · NA

    Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening

  • NCT06957366 · 920 participants · NA

    Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00055224, the US trial registry maintained by the National Library of Medicine. NCT00055224 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.